Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Syed I. Mobin

Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Central Florida Pulmonary Group
1115 East Ridgewood Street, 
Orlando, FL 
Accepting New Patients
Offers Telehealth
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Central Florida Pulmonary Group
1115 East Ridgewood Street, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Syed Mobin is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Orlando, Florida. Dr. Mobin is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pleurisy, Pleural Effusion, Bronchiectasis, Small Cell Lung Cancer (SCLC), and Gastrostomy. Dr. Mobin is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Pulmonary Medicine
Intensive Care Medicine
Sleep Medicine
Licenses
Critical Care Medicine in FL
Hospital Affiliations
Adventhealth Orlando
Hca Florida Osceola Hospital
Languages Spoken
English
Arabic
Faroese
Hebrew
Hindi
Italian
Spanish
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Central Florida Pulmonary Group
1115 East Ridgewood Street, Orlando, FL 32803
Other Locations
Central Florida Pulmonary Group
7319 Stonerock Cir #106, Orlando, FL 32819

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Enrollment Status: Terminated
Publish Date: February 14, 2024
Intervention Type: Drug, Other
Study Drug: Deupirfenidone
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: September 08, 2022
Intervention Type: Other, Drug
Study Drug: KD025
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

1 Total Publications

Rare Case of Giant Asymptomatic Left Coronary Artery Aneurysm of 10 cm Associated with Coronary Cameral Fistula.
Rare Case of Giant Asymptomatic Left Coronary Artery Aneurysm of 10 cm Associated with Coronary Cameral Fistula.
Journal: Cureus
Published: January 17, 2019
Similar Doctors
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Amir Quefatieh
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Amir Quefatieh
Pulmonary Medicine | Intensive Care Medicine

Florida Hospital Physician Group Inc

6719 Gall Blvd, Suite 208, 
Zephyrhills, FL 
 (54.5 miles away)
813-780-8778
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Amir Quefatieh is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Zephyrhills, Florida. Dr. Quefatieh is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Atypical Pneumonia, Hospital-Acquired Pneumonia, and Gastrostomy. Dr. Quefatieh is currently accepting new patients.

Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Shakti Narain
Pulmonary Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Shakti Narain
Pulmonary Medicine

Shakti Narain MD PA

1070 Flagler Ave, 
Leesburg, FL 
 (33.9 miles away)
352-365-2550
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Shakti Narain is a Pulmonary Medicine provider in Leesburg, Florida. Dr. Narain is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma, Endoscopy, and Advanced Bronchoscopy. Dr. Narain is currently accepting new patients.

Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dana L. Anctil, NP
Nurse Practitioner | Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dana L. Anctil, NP
Nurse Practitioner | Intensive Care Medicine

Orlando Health Medical Group Inc

86 W Underwood St, 
Orlando, FL 
 (3.3 miles away)
407-896-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dana Anctil is a Nurse Practitioner specialist and an Intensive Care Medicine provider in Orlando, Florida. Ms. Anctil is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top area of expertise is Heart Failure with Preserved Ejection Fraction (HFpEF). Ms. Anctil is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mobin's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile